CTNM
Contineum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.79
+1.03%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -14.3%
- EBIT
- —
- EPS
- +24.4%
- Free cash flow
- +1.1%
- Operating cash flow
- +1.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +76.1%
- EPS
- -3.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- -61.3%
- EBIT
- -33.7%
- Net income
- -41.9%
- EPS
- -33.1%
- Free cash flow
- -66.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026